3 hours Ago By ABMN Staff
InterCure ( NASDAQ:INCR – Get Free Report ) and Immunic ( NASDAQ:IMUX – Get Free Report ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends. Profitability This table compares InterCure and Immunic’s net margins, return on equity and return on assets. Valuation & Earnings This table compares InterCure and Immunic”s gross revenue, earnings per share (EPS) and valuation.
Institutional & Insider Ownership 8.3% of InterCure shares are owned by institutional investors. Comparatively, 51.
8% of Immunic shares are owned by institutional investors. 3.0% of Immunic shares are owned by company insiders.
Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Risk and Volatility InterCure has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.
Comparatively, Immunic has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Analyst Recommendations This is a summary of current recommendations and price targets for InterCure and Immunic, as reported by MarketBeat.
Immunic has a consensus price target of $11.80, suggesting a potential upside of 935.09%.
Given Immunic’s stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than InterCure. Summary Immunic beats InterCure on 7 of the 11 factors compared between the two stocks. About InterCure ( Get Free Report ) InterCure Ltd.
, together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector.
The company was incorporated in 1994 and is headquartered in Herzliya, Israel. About Immunic ( Get Free Report ) Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.
Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc.
was founded in 2016 and is headquartered in New York, New York. Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter .
.
